

Identification of therapeutic targets in patients with Squamous Cell Carcinoma of the Head and Neck who progress on or after anti-PD-(L)1 therapy - A IMMUcan sub-project



A. van der Elst^{1,2}, M. Morfouace^{2,5}, H.S. Hong^{3,5}, R. Liechti^{4,5}, J.-P. Machiels^{1,6}





R/M SCCHN

Recurrent and/or metastatic Squamous Cell Carcinoma of the Head and Neck



Nivolumab and pembrolizumab: ORR 10-20% -> only a minority of patients respond

No standard of care exists for patients who progress after platinum-based or anti-PD-1 therapy -> median overall survival is dismal (5-6 months)

IMMUcan



A public-private EU-funded translational research study to generate broad molecular and cellular profiling data of tumors and their microenvironment

Will screen up to 3,000 patients with:









Includes prospective cohorts and collaborates with clinical trials.

EORTC-HNCG-1559 Translational project

EORTC-HNCG-1559 or UPSTREAM TRIAL:

Biomarker-driven umbrella trial Enrolls R/M SCCHN patients previously treated or not with anti-PD-(L)1 therapy

Tumor biopsies performed at enrolment into the 1559 trial

⁴SIB. Lausanne. Switzerland

Analyses performed in IMMUcan:

- Whole exome sequencing
- RNA sequencing
- Multiplex immunofluorescence
- Imaging Mass Cytometry and correlation with clinical data

Characterization of the molecular and cellular profile of R/M SCCHN in regards to primary or secondary resistance to anti-PD-(L)1 therapy

targets Guide the development of rational therapeutic combinations

Identify therapeutic

The IMMUcan project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 821558. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. IMI.europa.eu. More information about IMMUcan: www.immucan.eu

¹Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain (UCLouvain), Brussels, Belgium athenais.vanderelst@uclouvain.be

²Translational research, EORTC, Brussels, Belgium

³Merck KGaA, Darmstadt, Germany

⁵on behalf of the IMMUcan consortium ⁶Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium